SCHEMBL20980452

SCHEMBL20980452

COc1ccc(COc2nc(Cl)nc(Oc3cccnc3)c2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
DRD4 P21917 1/20 0.40
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CNR1 P21554 2/20 0.39
CNR2 P34972 2/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
GRM5 P41594 1/20 0.39
CSF1R P07333 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
LRRK2 Q5S007 1/20 0.38
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20957936 0.86 RAB9A (0.39) CYP17A1RAB9ANPC1DRD4MAPT
SCHEMBL20980464 0.78 SMN1; SMN2 (0.44) RAB9ANPC1NPSR1CNR1CNR2
SCHEMBL20564797 0.77 HTT (0.42) CYP17A1RAB9ANPC1CNR1CNR2
SCHEMBL30876508 0.77 RAB9A (0.60) RAB9ANPC1DRD4MAPTNPSR1
SCHEMBL31138541 0.72 CNR2 (0.48) CYP17A1RAB9ANPC1NPSR1CNR1
SCHEMBL9987222 0.72 CNR1 (0.44) CYP17A1RAB9ANPC1CNR1CNR2
SCHEMBL3938617 0.71 MAOB (0.52) RAB9ANPC1MAPTNPSR1CYP11B1
SCHEMBL11107948 0.69 LMNA (0.62) CYP17A1RAB9ANPC1CYP11B1CYP11B2
SCHEMBL3196355 0.69 CNR1 (0.43) RAB9ANPC1NPSR1CNR1CNR2
SCHEMBL22323930 0.69 APP (0.50) RAB9ANPC1CNR1CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE KDM5A, KDM5B, KDM5C CYP17A1 2136/4885RAB9A 3556/4885NPC1 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.